Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis

Background: The metabolic syndrome (MetS) is a cluster of risk factors linked to insulin resistance that increase an individual's risk of atherosclerotic vascular disease. The authors evaluated the prevalence and prognosis of the MetS among individuals with symptomatic intracranial arterial stenosis. Methods: Patients enrolled in the Warfarin–Aspirin Symptomatic Intracranial Disease trial were evaluated in this post-hoc analysis. Baseline characteristics and outcome were compared in patients with the MetS vs patients without the MetS. Results: Among 476 patients, the prevalence of the MetS was 43%. MetS patients were more likely to be younger, female, and white. During a mean follow-up period of 1.8 years, time to the first of ischemic stroke, myocardial infarction, or vascular death was shorter among patients with the MetS with a hazard ratio (syndrome/no syndrome) of 1.6 (95% CI = 1.1 to 2.4, p = 0.0097). Time to ischemic stroke alone was also shorter among patients with the MetS with a hazard ratio (syndrome/no syndrome) of 1.7 (95% CI = 1.1 to 2.6, p = 0.012). When controlling for individual factors of the definition, MetS was not significant (combined outcome: p = 0.14; ischemic stroke: p = 0.074). Conclusions: The metabolic syndrome is present in about half of individuals with symptomatic intracranial atherosclerotic disease and is associated with a substantially higher risk of major vascular events. The metabolic syndrome may not provide additional ability to predict outcomes beyond the individual factors for patients with intracranial stenosis.

[1]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[2]  R. Kahn,et al.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.

[3]  S. Kasner,et al.  Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. , 2005, The New England journal of medicine.

[4]  P. Gorelick,et al.  Impact of obesity and the metabolic syndrome on risk factors in African American stroke survivors: a report from the AAASPS. , 2005, Archives of neurology.

[5]  P. Wilson,et al.  Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. , 2004, Endocrinology and metabolism clinics of North America.

[6]  D. Collet.  Modelling Survival Data in Medical Research , 2004 .

[7]  A. Algra,et al.  Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. , 2004, Atherosclerosis.

[8]  S. Reis,et al.  Metabolic Syndrome Modifies the Cardiovascular Risk Associated With Angiographic Coronary Artery Disease in Women: A Report From the Women’s Ischemia Syndrome Evaluation , 2004, Circulation.

[9]  Tracey McLaughlin,et al.  Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin Resistant , 2003, Annals of Internal Medicine.

[10]  M. Davidson.  Is treatment of insulin resistance beneficial independent of glycemia? , 2003, Diabetes care.

[11]  M. Jensen,et al.  Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. , 2003, Diabetes care.

[12]  Richard Hellman,et al.  American College of Endocrinology position statement on the insulin resistance syndrome. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[13]  A. Mokdad,et al.  Trends in waist circumference among U.S. adults. , 2003, Obesity research.

[14]  K. Nakao,et al.  Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. , 2003, Diabetes care.

[15]  F. Yalçin,et al.  Association between the metabolic syndrome and newly diagnosed coronary artery disease. , 2003, Diabetes, nutrition & metabolism.

[16]  C. Viscoli,et al.  Impaired insulin sensitivity among nondiabetic patients with a recent TIA or ischemic stroke , 2003, Neurology.

[17]  Harry J. Cloft,et al.  Design, Progress and Challenges of a Double-Blind Trial of Warfarin versus Aspirin for Symptomatic Intracranial Arterial Stenosis , 2003, Neuroepidemiology.

[18]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[19]  L. Niskanen,et al.  Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. , 2002, American journal of epidemiology.

[20]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[21]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[22]  E. Ferrannini,et al.  Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). , 1997, The Journal of clinical investigation.

[23]  B. Ovbiagele.  Association of the metabolic syndrome with intracranial atherosclerotic stroke. , 2006, Neurology.

[24]  B. Boden–Albala.  Stroke risk and the metabolic syndrome : findings from the Northern Manhattan Study , 2003 .

[25]  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2002, Circulation.

[26]  P. Grandjean.  Report on a WHO consultation , 1991 .

[27]  R. Govindan,et al.  Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Management of Patients with Advanced Non-small Cell Lung Cancer: Role of Gefitinib , 2022 .